ARCT NASDAQ
Arcturus Therapeutics Holdings Inc.
1W: -5.9%
1M: -22.2%
3M: +77.3%
YTD: +108.5%
1Y: -36.4%
3Y: -52.1%
5Y: -74.3%
$13.03
-0.18 (-1.36%)
Weekly Expected Move ±10.8%
$10
$12
$13
$14
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-08-04
Earliest Filing
2023-09-26
Latest Filing
partner: 6
customer: 1
Counterparties (Filed by ARCT)
7 relationshipsCompanies named in ARCT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cystic Fibrosis Foundation | — | partner | Amendment to Development Program Letter Agreement increasing award amount and modifying royalty terms | 2023-09-26 | View |
| Seqirus, Inc. | — | partner | Collaboration partner receiving $17.5 million milestone payment for LUNAR-FLU program | 2023-08-14 | View |
| CSL Seqirus | — | partner | Parent entity of Seqirus, Inc. under the CSL Collaboration Agreement | 2023-08-14 | View |
| CSL Seqirus, Inc. | — | partner | Entered into a Collaboration and License Agreement for research, development, and commercialization of self-amplifying m | 2022-11-02 | View |
| Israeli Ministry of Health | — | customer | Termination of Supply Agreement for first-generation COVID-19 vaccine candidate | 2022-04-20 | View |
| Vinbiocare Biotechnology Joint Stock Company | — | partner | Collaborator sponsoring Phase 1/2/3 Study for ARCT-154 vaccine candidate | 2022-04-20 | View |
| Vinbiocare Biotechnology Joint Stock Company | — | partner | Collaboration to establish a manufacturing facility in Vietnam for COVID-19 vaccines including a technology license and | 2021-08-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-23 | Regulation FD; Exhibits | View | |
| 2026-08-25 | Regulation FD; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-02 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-22 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-30 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-24 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR